Parathyroid hormone measurement in chronic kidney disease – an evolving issue for the nephrologist and the clinical laboratorist: minireview

References

• Friedman, P.A., Goodman, W.G. PTH(1-84)/PTH(7-84): A balance of power. Am J Physiol Renal Physiol 2006, 290, 975–984.
   PubMed Web of Science ®Google Scholar
• Urena Torres, P. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006, 70, 240–243.
   PubMedGoogle Scholar
• Riccardi, D., Brown, E.M. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 2010, 298, 485–499.
   PubMed Web of Science ®Google Scholar
• Brown, E.M. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007, 3, 122–133.
   PubMedGoogle Scholar
• Murray, T.M., Rao, L.G., Divieti, P., Bringhurst, F.R. Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocr Rev 2005, 26, 78–113.
   PubMed Web of Science ®Google Scholar
• Usdin, T.B., Bonner, T.I., Hoare, S.R. The parathyroid hormone 2 (PTH2) receptor. Recept Channels 2002, 8, 211–218.
   PubMedGoogle Scholar
• Brown, E.M. (2001). Physiology of calcium homeostasis. In: Bilezikian, J.P., Marcus, R., Levine, A. eds. The parathyroids. Second edition. Chapter 10. San Diego, USA: Academic Press Inc. pp: 167–182.
   Google Scholar
• Ma, Y.L., Cain, R.L., Halladay, D.L., Yang, X., Zeng, Q., Miles, R.R., Chandrasekhar, S., Martin, T.J., Onyia, J.E. Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001, 142, 4047–4054.
   PubMed Web of Science ®Google Scholar
• Deftos, L. Calcium and phosphate homeostasis (updated May 17, 2010). In: Arnold, A., ed. Diseases of bone and mineral metabolism. Available at: http://www.endotext.org. Accessed on 31 August 2011.
   Google Scholar
• Qin, L., Raggatt, L.J., Partridge, N.C. Parathyroid hormone: A double-edged sword for bone metabolism. Trends Endocrinol Metab 2004, 15, 60–65.
   PubMed Web of Science ®Google Scholar
• Levey, A.S., Atkins, R., Coresh, J., Cohen, E.P., Collins, A.J., Eckardt, K.U., Nahas, M.E., Jaber, B.L., Jadoul, M., Levin, A., Powe, N.R., Rossert, J., Wheeler, D.C., Lameire, N., Eknoyan, G. Chronic kidney disease as a global public health problem: Approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int 2007, 72, 247–259.
   PubMed Web of Science ®Google Scholar
• London, G., Coyne, D., Hruska, K., Malluche, H.H., Martin, K.J. The new kidney disease: Improving global outcomes (KDIGO) guidelines - expert clinical focus on bone and vascular calcification. Clin Nephrol 2010, 74, 423–432.
   PubMed Web of Science ®Google Scholar
• Moe, S., Drüeke, T., Cunningham, J., Goodman, W., Martin, K., Olgaard, K., Ott, S., Sprague, S., Lameire, N., Eknoyan, G. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2006, 69, 1945–1953.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009, 76, 1–130.
   Google Scholar
• National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42, 1–200.
   PubMed Web of Science ®Google Scholar
• Morrone, L.G., Russo, D., Di Iorio, B. Diagnostic workup for disorders of bone and mineral metabolism in patients with chronic kidney disease in the era of KDIGO guidelines. Int J Nephrol 2011 art ID 958798, 6 pages.
   PubMedGoogle Scholar
• Pontoriero, G., Cozzolino, M., Locatelli, F., Brancaccio, D. CKD patients: The dilemma of serum PTH levels. Nephron Clin Pract 2010, 116, c263–c268.
   Google Scholar
• Drueke, T.B. Hyperparathyroidism in chronic kidney disease. (updated 1 October 2009). In: Arnold, A., ed. Diseases of bone and mineral metabolism. Available at: http://www.endotext.org. Accessed on 31 August 2011.
   Google Scholar
• Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G., Chertow, G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15, 2208–2218.
   PubMed Web of Science ®Google Scholar
• Cunningham, J., Silver, J. CKD-MBD: Comfort in the trough of the U. Nephrol Dial Transplant 2011, 26, 1764–1766.
   PubMedGoogle Scholar
• Cantor, T., Yang, Z., Caraiani, N., Ilamathi, E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions. Clin Chem 2006, 52, 1771–1776.
   PubMedGoogle Scholar
• Souberbielle, J.C., Roth, H., Fouque, D.P. Parathyroid hormone measurement in CKD. Kidney Int 2010, 77, 93–100.
   PubMedGoogle Scholar
• Joly, D., Drueke, T.B., Alberti, C., Houillier, P., Lawson-Body, E., Martin, K.J., Massart, C., Moe, S.M., Monge, M., Souberbielle, J.C. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study. Am J Kidney Dis 2008, 51, 987–995.
   PubMedGoogle Scholar
• Souberbielle, J.C., Friedlander, G., Cormier, C. Practical considerations in PTH testing. Clin Chim Acta 2006, 366, 81–89.
   PubMedGoogle Scholar
• Cavalier, E., Delanaye, P., Carlisi, A., Krzesinski, J.M., Chapelle, J.P. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007, 72, 370–372.
   PubMedGoogle Scholar
• Marangella, M. PTH measurement: Where do we stand?. G Ital Nefrol 2009, 26, 600–607.
   PubMedGoogle Scholar
• D’Amour, P., Brossard, J.H., Rousseau, L., Roy, L., Gao, P., Cantor, T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003, 49, 2037–2044.
   PubMedGoogle Scholar
• D’Amour, P., Räkel, A., Brossard, J.H., Rousseau, L., Albert, C., Cantor, T. Acute regulation of circulating parathyroid hormone (PTH) molecular forms by calcium: utility of PTH fragments/PTH(1-84) ratios derived from three generations of PTH assays. J Clin Endocrinol Metab 2006, 91, 283–289.
   PubMedGoogle Scholar
• D’Amour, P., Brossard, J.H. Carboxyl-terminal parathyroid hormone fragments: Role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005, 14, 330–336.
   PubMedGoogle Scholar
• Carrozza, C., Iavarone, F., Gervasoni, J., Zuppi, C. Problematiche del dosaggio del paratormone: valutazione del kit access intact PTH. Ligand Assay 2008, 13, 34–39.
   Google Scholar
• Nussbaum, S.R., Zahradnik, R.J., Lavigne, J.R., Brennan, G.L., Nozawa-Ung, K., Kim, L.Y., Keutmann, H.T., Wang, C.A., Potts, J.T. Jr, Segre, G.V. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987, 33, 1364–1367.
   PubMed Web of Science ®Google Scholar
• Lepage, R., Roy, L., Brossard, J.H., Rousseau, L., Dorais, C., Lazure, C., D’Amour, P. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998, 44, 805–809.
   PubMed Web of Science ®Google Scholar
• Slatopolsky, E., Finch, J., Clay, P., Martin, D., Sicard, G., Singer, G., Gao, P., Cantor, T., Dusso, A. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000, 58, 753–761.
   PubMed Web of Science ®Google Scholar
• Souberbielle, J.C., Boutten, A., Carlier, M.C., Chevenne, D., Coumaros, G., Lawson-Body, E., Massart, C., Monge, M., Myara, J., Parent, X., Plouvier, E., Houillier, P. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006, 70, 345–350.
   PubMed Web of Science ®Google Scholar
• Souberbielle, J.C., Cavalier, E., Jean, G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: What do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med 2010, 48, 769–774.
   PubMed Web of Science ®Google Scholar
• John, M.R., Goodman, W.G., Gao, P., Cantor, T.L., Salusky, I.B., Jüppner, H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999, 84, 4287–4290.
   PubMed Web of Science ®Google Scholar
• Gao, P., Scheibel, S., D’Amour, P., John, M.R., Rao, S.D., Schmidt-Gayk, H., Cantor, T.L. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001, 16, 605–614.
   PubMedGoogle Scholar
• Räkel, A., Brossard, J.H., Patenaude, J.V., Albert, C., Nassif, E., Cantor, T., Rousseau, L., D’Amour, P. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf) 2005, 62, 721–727.
   PubMedGoogle Scholar
• Taniguchi, M., Tanaka, M., Hamano, T., Nakanishi, S., Fujii, H., Kato, H., Koiwa, F., Ando, R., Kimata, N., Akiba, T., Kono, T., Yokoyama, K., Shigematsu, T., Kakuta, T., Kazama, J.J., Tominaga, Y., Fukagawa, M. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 2011, 15, 42–49.
   PubMedGoogle Scholar
• Martin, K.J., Jüppner, H., Sherrard, D.J., Goodman, W.G., Kaplan, M.R., Nassar, G., Campbell, P., Curzi, M., Charytan, C., McCary, L.C., Guo, M.D., Turner, S.A., Bushinsky, D.A. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005, 68, 1236–1243.
   PubMedGoogle Scholar
• Melamed, M.L., Eustace, J.A., Plantinga, L.C., Jaar, B.G., Fink, N.E., Parekh, R.S., Coresh, J., Yang, Z., Cantor, T., Powe, N.R. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: The CHOICE study. Nephrol Dial Transplant 2008, 23, 1650–1658.
   PubMedGoogle Scholar
• Cavalier, E., Daly, A.F., Betea, D., Pruteanu-Apetrii, P.N., Delanaye, P., Stubbs, P., Bradwell, A.R., Chapelle, J.P., Beckers, A. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010, 95, 3745–3749.
   PubMedGoogle Scholar
• Caron, P., Simonds, W.F., Maiza, J.C., Rubin, M., Cantor, T., Rousseau, L., Bilezikian, J.P., Souberbielle, J.C., D’Amour, P. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: A possible link to HRPT2 gene inactivation. Clin Endocrinol (Oxf) 2011, 74, 694–698.
   PubMedGoogle Scholar
• Cavalier, E., Rousselle, A.O., Bekaert, A.C., Carlisi, A., Chapelle, J.P., Delanaye, P. Evaluation of Diasorin Liaison 1-84 PTH assay, a new automated immunoassay for the determination of 3rd generation PTH. AACC Annual Meeting 2010 abstract.
   Google Scholar
• Zanelli, J.M., Gaines-Das, R.E. The first international reference preparation of human parathyroid hormone for immunoassay: Characterization and calibration by international collaborative study. J Clin Endocrinol Metab 1983, 57, 462–469.
   PubMedGoogle Scholar
• Rej, R., Drake, P. The nature of calibrators in immunoassays: Are they commutable with test samples? must they be? Scand J Clin Lab Invest Suppl 1991, 205, 47–54.
   PubMedGoogle Scholar
• WHO Document from Expert Committee on Biological Standardization, Geneva, 19 to 23 October 2009. WHO/BS/09.2115.
   Google Scholar
• Souberbielle, J.C., Cormier, C., Kindermans, C., Gao, P., Cantor, T., Forette, F., Baulieu, E.E. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001, 86, 3086–3090.
   PubMedGoogle Scholar